Literature DB >> 23219433

Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model.

Mustafa Bakir1, Baudouin Standaert, Ozden Turel, Zeynep Ece Bilge, Maarten Postma.   

Abstract

BACKGROUND: The burden of rotavirus disease is high in Turkey, reflecting the large birth cohort (>1.2 million) and the risk of disease. Modelling can help to assess the potential economic impact of vaccination. We compared the output of an advanced model with a simple model requiring fewer data inputs. If the results are similar, this could be helpful for countries that have few data available.
METHODS: The advanced model was a previously published static Markov cohort model comparing costs and quality-adjusted life-year (QALY) outcomes of vaccination versus no vaccination. In contrast, the simple model used only a decision tree. Both models included data on demography, epidemiology, vaccine efficacy, resource use, unit costs, and utility scores from national databases and published papers. Only the perspective of the health care payer was considered in the analysis. The simple model had 23 variables, compared with 103 in the advanced model to allow additional comparisons of different vaccine types, dose schemes and vaccine waning.
RESULTS: With the same input data, both models showed that rotavirus vaccination in Turkey would improve health outcomes (fewer QALYs lost to rotavirus disease). The projected annual cost offsets were $29.9 million in the simple and $29.4 million in the advanced model. Sensitivity analysis indicated that in both models the main cost driver was disease incidence followed by cost for hospital care and medical visits. Vaccine efficacy had a smaller effect.
CONCLUSION: Both models reached similar conclusions. Both projected that rotavirus vaccination in Turkey would improve health outcomes and may result in savings in direct healthcare costs to offset the cost of vaccination. The analysis indicated that the simple model can produce meaningful economic results in conditions where few data are available.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219433     DOI: 10.1016/j.vaccine.2012.11.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Systematic review of the economic value of diarrheal vaccines.

Authors:  Richard Rheingans; Mirna Amaya; John D Anderson; Poulomy Chakraborty; Jacob Atem
Journal:  Hum Vaccin Immunother       Date:  2014-05-27       Impact factor: 3.452

2.  Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?

Authors:  Baudouin Standaert; Olivier Ethgen; Rachel Emerson; Maarten Postma; Josephine Mauskopf
Journal:  Adv Ther       Date:  2014-10-21       Impact factor: 3.845

3.  Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi.

Authors:  Fulgence Niyibitegeka; Montarat Thavorncharoensap; Arthorn Riewpaiboon; Sitaporn Youngkong
Journal:  Appl Health Econ Health Policy       Date:  2022-04-26       Impact factor: 3.686

4.  Economic Evaluation of Human Rotavirus Vaccine in Thailand.

Authors:  Surasak Saokaew; Wasana Prasitsuebsai; Gyneth Lourdes Bibera; Kirati Kengkla; Xu-Hao Zhang; Kyu-Bin Oh; Christa Lee
Journal:  Infect Dis Ther       Date:  2019-06-13

5.  Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.

Authors:  Marisa Holubar; Maria Christina Stavroulakis; Yvonne Maldonado; John P A Ioannidis; Despina Contopoulos-Ioannidis
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

Review 6.  Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.

Authors:  Siyu Ma; Tara A Lavelle; Daniel A Ollendorf; Pei-Jung Lin
Journal:  Appl Health Econ Health Policy       Date:  2022-01-10       Impact factor: 3.686

7.  Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data.

Authors:  Koen B Pouwels; Sefika E Bozdemir; Selen Yegenoglu; Solmaz Celebi; E David McIntosh; Serhat Unal; Maarten J Postma; Mustafa Hacimustafaoglu
Journal:  PLoS One       Date:  2016-09-30       Impact factor: 3.240

8.  Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model.

Authors:  Salem Alkoshi; Namaitijiang Maimaiti; Maznah Dahlui
Journal:  Libyan J Med       Date:  2014-12-09       Impact factor: 1.743

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.